Tecvayli : EPAR - Product Information

Human medicines European public assessment report (EPAR): Trelegy Ellipta, fluticasone furoate,umeclidinium,vilanterol, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 15/11/2017, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Raxone, idebenone, Optic Atrophy, Hereditary, Leber, Date of authorisation: 08/09/2015, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms, Date of authorisation: 19/06/2015, Revision: 56, Status: Authorised

Human medicines European public assessment report (EPAR): Elebrato Ellipta, fluticasone furoate,umeclidinium,vilanterol, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 15/11/2017, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Adtralza, tralokinumab, Dermatitis, Atopic, Date of authorisation: 17/06/2021, Revision: 4, Status: Authorised

Mefloquine: List of nationally authorised medicinal products - PSUSA/00000304/202303

Human medicines European public assessment report (EPAR): Advagraf, tacrolimus, Graft Rejection, Date of authorisation: 23/04/2007, Revision: 26, Status: Authorised

SPOR and xEVMPD Stakeholder Engagement Webinars : Substance, product, organisation and referential (SPOR) application programming interface (API) - SPOR API, Online, from 12/10/2023 to 12/10/2023

SPOR and xEVMPD Stakeholder Engagement Webinars : Organisation Management Service (OMS), Online, from 04/10/2023 to 04/10/2023